Immune checkpoint inhibitor-induced diabetes can potentially be effectively treated with infliximab: a case report of two patients
Open Access
- 7 November 2025
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 16, 1697724
Abstract
Immune checkpoint inhibitor-induced diabetes is a potentially severe and life-threatening complication of immune checkpoint inhibitor therapy in patients with advanced malignancies. It is typically an irreversible complication due to the complete destruction of pancreatic beta cells that requires ongoing insulin treatment, and patients often exhibit labile diabetes. Inflammatory cytokines, including TNF-α, are thought to play a role in the development of this form of diabetes, as they do in spontaneous autoimmune diabetes. TNF-α has also been implicated in the development of other immune-related adverse events caused by immunotherapy, and infliximab, a TNF-α monoclonal antibody, has shown efficacy in several of these complications. We tested whether infliximab could preserve beta-cell function in immune checkpoint inhibitor-induced diabetes. We present two cases in which infliximab treatment appeared to halt beta-cell destruction, as evidenced by maintenance of C-peptide levels, as well as improved clinical outcomes in terms of diabetes control.Keywords
This publication has 13 references indexed in Scilit:
- Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetesJCI Insight, 2022
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse eventsJournal for ImmunoTherapy of Cancer, 2021
- TNF in the era of immune checkpoint inhibitors: friend or foe?Nature Reviews Rheumatology, 2021
- Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint InhibitorsAnnual Review of Medicine, 2021
- Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literatureReviews in Endocrine and Metabolic Disorders, 2021
- Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 DiabetesNew England Journal of Medicine, 2020
- Successful Treatment of Immune Checkpoint Inhibitor–Induced Diabetes With InfliximabDiabetes Care, 2019
- Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitisJournal for ImmunoTherapy of Cancer, 2019
- Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in MelanomaJAMA Oncology, 2018
- Etanercept Treatment in Children With New-Onset Type 1 DiabetesDiabetes Care, 2009